Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,627,990.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, November 13th. The stock was sold at an average price of $592.42, for a total value of $5,627,990.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $192,206,522.06. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $3.29 during mid-day trading on Monday, reaching $587.88. 424,498 shares of the company were exchanged, compared to its average volume of 553,937. The firm has a market cap of $25.04 billion, a price-to-earnings ratio of 22.18, a P/E/G ratio of 3.93 and a beta of 0.49. The firm’s 50-day simple moving average is $542.60 and its 200 day simple moving average is $536.37. United Therapeutics Corporation has a 1 year low of $455.63 and a 1 year high of $614.23.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.16 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 25.08 earnings per share for the current fiscal year.

United Therapeutics announced that its Board of Directors has approved a stock buyback program on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Institutional Trading of United Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Toth Financial Advisory Corp grew its holdings in shares of United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. Fiduciary Financial Advisors acquired a new position in United Therapeutics during the second quarter valued at approximately $30,000. Gen Wealth Partners Inc bought a new position in shares of United Therapeutics in the third quarter valued at approximately $34,000. Caitlin John LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth $37,000. Finally, International Assets Investment Management LLC increased its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. Leerink Partners increased their price objective on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. HC Wainwright began coverage on shares of United Therapeutics in a research report on Monday, November 9th. They issued a “buy” rating and a $660.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a report on Monday, October 26th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a report on Wednesday, October 28th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research note on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $676.40.

View Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Read More

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.